Abstract 298: Dissection of drug-protein interactions by HR-LiP-MS in target validation and lead optimization
Authors: Nigel Beaton, Jagat Adhikari, Yuehan Feng, Roland Bruderer, Ron Tomlinson, Ivan Cornella-Taracido, Lukas Reiter
Journal: Cancer Research (2021)

Abstract Background A central focus of preclinical drug discovery is the thorough characterization of lead compounds. This is a key step that helps ensure that drug candidates are worthy of clinical testing. In addition to phenotypic characterization, quantitative profiling of drug-protein interactions is a major hurdle during preclinical lead optimization. Traditionally, the gold standard technique informing structure-based drug design has been x-ray crystallography, despite the fact that under crystallization conditions protein conformation is frozen and aspects of protein structural transitions are neglected by this approach. More recently, hydrogen-deuterium exchange (HDX) has emerged as an alternative tool to profile ligand-protein interactions. While correlation of HDX-profiles with functional readouts provides valuable insights into structure-activity relations (SAR), the method itself can be laborious with extensive optimization required to generate high quality data. To address some of these shortcomings, we developed a high-throughput approach based on limited proteolysis (LiP) and next-generation quantitative mass spectrometry that enables the dissection of drug-protein interactions at peptide-level resolution. Methods To simulate the complex protein mixture obtained from cell lysis, purified recombinant proteins were spiked into a cell lysate background. Next, the mixtures were incubated with the compounds of interest. The samples were subjected to limited digestion with proteinase K and subsequently processed to peptides with trypsin for DIA-MS analysis. MS data were analyzed using a DirectDIA-workflow. Results High-Resolution Limited Proteolysis (HR-LiP) was established using calmodulin and its robust interactions with Ca2+ ions and CAMKII peptide as a model system. From here, we expanded the technique to small molecule-protein interactions of established, druggable protein targets spanning several protein classes. Herein we demonstrate that using HR-LiP we are able to identify binding sites of various compound classes on their target proteins including well characterized small molecules such as the BRD4 inhibitor JQ1. HR-LiP data are in good accordance with orthogonal HDX-MS, NMR and X-ray studies. Conclusions We demonstrate that HR-LiP can be used to dissect small molecule-protein binding characteristics with a resolution of 5-10 amino acids. Quantitative properties of the binding events are accurately recapitulated in dosage series and can therefore be deployed to rank and compare different compounds and compound classes. The ability to deal with complex backgrounds and unpurified proteins enables its application on difficult-to-purify or unstable proteins, and potentially multi-protein complexes. We envision the application of HR-LiP as a routine approach for target validation and lead optimization in small molecule drug discovery pipelines. Citation Format: Nigel Beaton, Jagat Adhikari, Yuehan Feng, Roland Bruderer, Ron Tomlinson, Ivan Cornella-Taracido, Lukas Reiter. Dissection of drug-protein interactions by HR-LiP-MS in target validation and lead optimization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 298.